Nkarta Inc (NAS:NKTX)
$ 2.87 -0.12 (-4.01%) Market Cap: 202.53 Mil Enterprise Value: 4.93 Mil PE Ratio: 0 PB Ratio: 0.47 GF Score: 38/100

Nkarta Inc Business Update Call Transcript

May 06, 2021 / 08:30PM GMT
Release Date Price: $25.92 (-5.30%)
Operator

Good day, everyone, and welcome to today's Nkarta business update call. (Operator Instructions) And it is now my pleasure to turn the conference over to Greg Mann. Please go ahead.

Greg Mann

Thank you, Rylene, and good afternoon, everyone. I'm Greg Mann, Vice President of Investor Relations and Public Affairs at Nkarta. Thank you for joining us to discuss Nkarta's new strategic partnership with CRISPR Therapeutics to transform the power of natural killer cells against cancer. Paul Hastings, President and CEO of Nkarta; and Nadir Mahmood, Chief Financial and Business Officer of Nkarta, will review the details of the collaboration. We'll then open the call to questions and will be joined by James Trager, Chief Scientific Officer; Kanya Rajangam, Chief Medical Officer; and Ralph Brandenberger, Senior Vice President of Technical Operations, all from Nkarta.

Before we begin our prepared remarks, we'd like to remind everyone that comments made by Nkarta management and responses to questions on this call will include forward-looking statements and information.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot